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Abstract
Given its prominent role in inflammation and cancer biology, the C-X-C motif chemokine receptor 4 (CXCR4) has gained a 
lot of attention in the recent years. This review gives a short overview of the physiology and pathology of chemokines and 
chemokine receptors and then focuses on the current experience of targeting CXCR4, using radiolabeled receptor ligands 
suitable for positron emission tomography (PET) imaging, in both hematologic and solid malignancy as well as in inflam-
matory conditions. Additionally, CXCR4-directed endoradiotherapy (ERT) as a new treatment option is discussed.
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Introduction
Chemokines and chemokine receptors
Chemokines are small, secreted proteins that are defined by 
their structurally important cystein residues, and therefore, 
grouped, according to the systemic nomenclature from 2000, 
into four subfamilies, namely CC, CXC,  CX3C and XC 
chemokines [1]. Chemokine receptors are named according 
to their respective ligand (chemokine) and are divided into 
two groups—conventional chemokine receptors (cCKRs) 
and atypical chemokine receptors (ACKRs) [2]. cCKRs 
belong to the family of G protein-coupled receptors, and 
therefore, typically signal via the MAPK- and β-arrestin 
pathway. ACKRs structurally resemble cCKRs but are not 
coupled to G proteins. Therefore, they are mainly involved 
in the scavenging and consequently the homeostasis of 
chemokines [3].
Role of CXCR4 and its ligand CXCL12 in physiology 
and pathology
The chemokine receptor CXCR4 is a seven transmembrane 
G protein-coupled receptor. CXCR4 is widely expressed 
throughout the human body during embryonic development 
and adult life, with uniquely high-expression levels in the 
hematopoietic system. Its cognate ligand, the chemokine 
CXCL12 (also named stromal cell-derived factor-1α, 
SDF-1α), is mainly expressed in the bone marrow (BM), 
lymph nodes, lung, heart, thymus and liver [4]. The canoni-
cal CXCR4-CXCL12 axis activates major cellular signaling 
pathways like RAS-MAPK, PI3K-AKT-mTOR, JAK-STAT 
and PLC. The β-arrestin pathway displays a negative feed-
back loop, leading to CXCR4 internalization and its lysoso-
mal degradation [5].
The outstanding role of the CXCR4-CXCL12 pathway 
within the chemokine network is emphasized by the fact 
that either a CXCR4 or CXCL12 deletion, by means of 
gene knockout, results in embryonic lethality in mice. This 
reflects the importance of the signaling axis during the 
development of the hematopoietic, nervous and cardio-
vascular system [6–8]. Apart from its role in organogen-
esis, CXCR4-CXCL12 signaling is crucially involved in 
the homeostasis of the adult hematopoietic system, mainly 
due to its implication in the retention of hematopoietic 
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stem cells in the BM niche [9]. Beyond, it orchestrates 
an adequate response of the adoptive and innate immune 
system.
However, the CXCR4 receptor has also been found to 
be involved in a variety of diseases. For example, it medi-
ates HIV-1 entry into T cells as a co-receptor, where it was 
first identified [10]. Furthermore, in rheumatoid arthritis, 
CXCR4-expressing  CD4+ memory T cells accumulate in 
the inflamed synovium due to the locally increased CXCL12 
concentration [11]. In the pathogenesis of atherosclerosis, 
CXCR4 is involved in the chronic inflammation of the arte-
rial wall which is characterized by a chemokine-mediated 
influx of leukocytes [12]. CXCR4 has also been identified as 
a key player in vascular remodeling after injury, atheroscle-
rotic plaque destabilization and aneurysm formation [13]. 
Moreover, chronic inflammation, and thus local infiltration 
with CXCR4-expressing immune cells, strongly promotes 
carcinogenesis of esophageal cancer [14]. Aside from its 
involvement in various inflammation-related processes, 
CXCR4 dysregulation was also found to significantly con-
tribute to neurodegenerative diseases [15].
CXCR4‑CXCL12 role in cancer
CXCR4 and CXCL12 play a pivotal role in tumor develop-
ment and metastasis [16, 17]. This has been demonstrated 
for a variety of cancer entities, including breast [18], prostate 
[19, 20], lung [21, 22] and colorectal cancer [23], as well 
as primary brain tumors such as glioblastoma [24]. Overall, 
the level of CXCR4 and CXCL12 expression is predictive 
for the metastatic potential of a given tumor type and medi-
ates organ-specific metastasis [25]. In fact, chemokines are 
at the center of molecular control of metastasis and tumor 
growth [26]. By activation of various signaling pathways, 
e.g., RAS-MAPK, PI3K-AKT-mTOR and JAK-STAT, the 
CXCL12-CXCR4 axis promotes tumor proliferation, inhib-
its apoptosis of cancerous cells and facilitates metastasis 
[27]. CXCL12 modulates the tumor microenvironment by 
autocrine and paracrine secretion. For instance, the attracted 
stromal cells are stimulated to secrete growth factors that 
support tumor proliferation and angiogenesis [27–30]. Fur-
ther, high CXCL12 levels—via the activation of NF-ĸB—
suppress the production of TNF-α which subsequently leads 
to a protection of tumor cells from entering apoptosis [31, 
32]. In addition, CXCL12 modulates the immune response 
to the tumor tissue, e.g., by recruiting dendritic cell popula-
tions. Those cells tolerate tumor tissue due to a dysfunction 
in their tumor-associated antigen-presentation to T cells, 
thereby promoting immunosuppression within the tumor 
microenvironment [33, 34]. Hence, the disruption of the 
CXCL12-CXCR4 axis provides a promising molecular tar-
get for future specific cancer therapies.
Targeting the CXCR4–CXCL12 axis
Given the undisputed clinical relevance of CXCR4 concern-
ing the growth and spreading of a variety of malignancies, 
a multitude of CXCR4-directed peptidic and non-peptidic 
antagonists have been developed during the last decade [16, 
28]. Amongst them, the bicyclam AMD3100 (Plerixafor/
Mozobil™) is the only compound that has been approved by 
the FDA (in 2008) for the mobilization of stem cells and for 
the treatment of hematological malignancies and other can-
cers [35–38]. In preclinical mouse models of various malig-
nancies, CXCR4-directed therapies using either alternative 
small-molecule CXCR4 antagonists such as AMD3465 
[39, 40] or MSX-122 [41], peptidic CXCL12 derivatives 
(CTCE-9908 [42], BKT-140 [43–45], POL-5551 [46–48]), 
anti-CXCR4-antibodies [49–52] or CXCL12 inhibitors such 
as the Spiegelmer Nox-A12 [53], have been shown to con-
sistently lead to prolonged overall survival, primarily by 
effectively preventing distant organ metastasis [54]. Another 
potent CXCR4 antagonist, LY2510924 (cyclo[Phe-Tyr-
Lys(iPr)-d-Arg-2-Nal-Gly-d-Glu]-Lys(iPr)-NH2) [55, 56], 
exhibited high antitumor activities in solid tumor and breast 
cancer metastatic models and is currently evaluated in phase 
II clinical trials. Recently, disulfide-bridged cyclic hepta-
peptide antagonists with excellent in vivo stability [57, 58] 
have been shown to efficiently inhibit lung metastasis in a 
melanoma model [59], and to reduce the metastatic potential 
of hepatocellular carcinoma and osteosarcoma in a mouse 
model [60]. A modified analog (R29, Ac-Arg-Ala-[d-Cys-
Arg-Phe-His-Pen]–COOH) efficiently reverts the suppres-
sive activity of T regulatory cells in renal cancer [61]. Lastly, 
overcoming chemoresistance in AML via RNA-interference 
within the CXCR4–CXCL12 axis was examined in a human 
AML xenograft model [62].
Tracer development for diagnosis and therapy
Based on these developments and to meet the clinical need 
for pre-therapeutic quantification of CXCR4 expression, 
intense efforts have also been directed towards the devel-
opment of suitable CXCR4-targeted molecular imaging 
agents [63, 64]. Amongst the mentioned CXCR4-targeted 
antagonists, three classes of compounds have been exten-
sively evaluated with respect to their suitability as in vivo 
CXCR4 imaging agents:
a. radiolabeled analogs of the bicyclams AMD3100 [65–
67] and AMD3465 [68–70],
b. 18F- or 68Ga-labeled T-140-based peptides for PET 
imaging as well as corresponding nuclear/fluorescent 
ligands for optical/SPECT imaging [71–78], and
505Annals of Nuclear Medicine (2018) 32:503–511 
1 3
c. radiolabeled, FC-131-based cyclic pentapeptides [79–
86].
From all three classes, highly promising candidates with 
high CXCR4 affinity and excellent CXCR4-targeting proper-
ties in vitro and in vivo in preclinical studies have emerged, 
and single representatives such as  [64Cu]AMD3100 [65], 
the T-140 analogue  [68Ga]NOTA-NFB [74] and the cyclic 
pentapeptide  [68Ga]Pentixafor [80, 85] have also been evalu-
ated in patients. Unfortunately, the clearance pattern of the 
first two compounds, both of which exhibit considerable to 
very high splenic and liver uptake in mice and humans, chal-
lenge their applicability for high contrast clinical imaging 
of CXCR4 expression. In contrast, the FC-131-derived ana-
logue  [68Ga]Pentixafor cyclo(D-Tyr1-D-[NMe]Orn2(AMBS-
[68Ga]DOTA)-Arg3-Nal4-Gly5) [79, 80, 85, 87, 88] shows 
high affinity and selectivity for human CXCR4, rapid renal 
excretion, and very low non-specific background accumu-
lation, allowing sensitive and high-contrast PET imaging 
of CXCR4-expressing tissues in vivo and thus is the only 
CXCR4-targeted imaging agent that has found broad clinical 
applicability so far.
Unfortunately, the pronounced sensitivity of the Pentixa-
for scaffold towards even minor structural modifications 
[82], that ultimately lead to strongly decreased CXCR4 
affinity, precludes the use of its 177Lu- or 90Y-labeled ver-
sion as the corresponding CXCR4-targeted endoradiothera-
peutic (ERT) agent within a theranostic concept. Thus, a 
closely related alternative peptide backbone (cyclo(d-3-iodo-
Tyr1-d-[NMe]Orn2-Arg3-Nal4-Gly5)) was chosen for the 
realization of a first CXCR4-targeted endoradiotherapeutic 
agent, namely Pentixather (cyclo(d-3-iodo-Tyr1-d-[NMe]
Orn2(AMBS-DOTA)-Arg3-Nal4-Gly5)) [84]. The efficacy 
and toxicity of Pentixafor/Pentixather-based CXCR4-tar-
geted theranostic approach was demonstrated in patient-
derived (PDX) and cell line-based xenograft mouse models 
of ALL and AML [89]. Here,  [68Ga]Pentixafor PET ena-
bled visualization of CXCR4-positive leukemic burden, and 
CXCR4-directed ERT with  [177Lu]Pentixather resulted in 
the efficient reduction of leukemia in leukemia-harboring 
tissues (spleen, bone marrow). Despite a substantial in vivo 
cross-fire effect to the leukemia microenvironment, mesen-
chymal stem cells subjected to ERT were viable and capable 
of supporting the growth and differentiation of non-targeted 
normal hematopoietic cells ex vivo [89].
CXCR4 imaging in oncology
Imaging hematologic malignancies
As a likely consequence of its high physiological expression 
on normal hematopoietic cells, CXCR4 surface levels are 
also particularly high in several hematologic malignancies, 
including non-Hodgkin lymphoma (NHL), multiple mye-
loma (MM), chronic lymphocytic leukemia (CLL) and acute 
myeloid leukemia (AML), with substantial heterogeneity 
between diseases and within single entities.
Thus, as a proof-of-concept, the first clinical applica-
tion of  [68Ga]Pentixafor for CXCR4-directed PET imaging 
has been carried out in patients with lymphoproliferative 
diseases, i.e., NHL and MM [85]. Since then, most experi-
ence with  [68Ga]Pentixafor PET imaging has been gained 
in patients with MM. In the first disease-specific, proof-of-
concept investigation Philipp-Abbrederis et al. showed that 
 [68Ga]Pentixafor PET was able to image disease manifesta-
tion in 10/14 patients with MM [90]. These results were 
confirmed in a larger study by Lapa et al. in which CXCR4 
overexpression was shown in lesions of 23/34 MM patients 
upon CXCR4-targeted PET imaging [91]. Importantly, in 
both studies, CXCR4-directed PET with  [68Ga]Pentixafor 
provided additional information concerning lesion numbers 
in comparison to  [18F]FDG PET.
Further proof-of-concept studies have shown the clinical 
applicability of  [68Ga]Pentixafor in AML and CLL. Herhaus 
et al. showed that in AML, where the CXCR4-CXCL12 axis 
is crucially involved in attraction and retention of leukemic 
cells into the protective BM niche, CXCR4-directed imag-
ing with  [68Ga]Pentixafor was able to identify patients with 
CXCR4-positive AML [92]. Another study with  [68Ga]
Pentixafor revealed that BM involvement in CLL patients is 
associated with a significant tracer uptake when compared 
to healthy BM [93].
Those studies clearly depict the potential of CXCR4-
directed PET imaging as a diagnostic marker in hemato-
logic malignancies. However, its application in the future 
might be more directed towards patient selection for per-
sonalized therapeutic concepts such as CXCR4-directed 
ERT, rather than to evaluate disease extent or analyze 
remission upon standard treatments. This is partially due 
to the highly dynamic CXCR4 expression levels that are 
particularly volatile after administration of chemotherapy 
[94]. Therefore, the in vivo determination of CXCR4 levels 
by means of PET outmatches CXCR4 expression determined 
by immunochemistry owing to its clinical applicability. In 
addition, in all the described hematologic malignancies there 
are either established conventional strategies (cytomorphol-
ogy, flow cytometry, immunohistochemistry), or molecular 
markers (serum markers such as immunofixation of mono-
clonal proteins, or minimal residual disease markers using 
PCR or sequencing technologies) or an elaborated and well-
established imaging modality, e.g.,  [18F]FDG PET, for the 
evaluation or control of remission available.
However, additional utility for response assessment might 
be found in CXCR4-directed PET imaging of lymphoma of 
the central nervous system. It is conceivable that in this lym-
phoma entity, the CXCR4-directed tracer  [68Ga]Pentixafor, 
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due to its better contrast characteristics compared to  [18F]
FDG PET in the CNS (unpublished data), may improve 
the current response criteria provided by the International 
Primary CNS Lymphoma Collaborative Group [95]. It has 
recently been shown that response assessment with PET/
CT in a patient with extranodal marginal zone lymphoma of 
the orbital cavities showed comparable results with  [68Ga]
Pentixafor and  [18F]FDG [96].
Imaging solid cancers
CXCR4 overexpression was also found in various solid can-
cers, including breast, prostate [18–20], lung and colorectal 
cancer [21–23]. In analogy with hematologic malignancies, 
high CXCR4 expression in solid tumors is associated with 
worse prognosis [16, 97]. Yet, first in vivo pilot studies with 
the CXCR4-directed PET tracer  [68Ga]Pentixafor revealed 
a more modest as well as heterogeneous, and in some cases 
absent detectable receptor expression in solid cancers, a 
finding contrary to the expected CXCR4 expression pro-
file from in vitro studies [98, 99]. Some solid tumor types, 
however, did show a pronounced overexpression of CXCR4. 
Two separate studies found intense, histologically proven 
CXCR4 expression in most patients with small cell lung can-
cer [100] as well as non-small cell lung cancer [101]. Fur-
thermore, Bluemel et al. demonstrated feasibility of  [68Ga]
Pentixafor imaging in patients with advanced adrenocortical 
cancer. In this theranostic approach, about 70% of patients 
showed sufficient CXCR4 expression to potentially qualify 
for CXCR4-directed radionuclide therapy [102]. A study by 
Werner et al. looking at the relationship between tumor grad-
ing in neuroendocrine tumors and receptor expression found 
that an increase in receptor expression correlates with higher 
tumor grade [103]. Furthermore, in a recently published 
study, Fang et al. showed increased CXCR4 expression in 
esophageal malignancies, with most of the signal coming 
from immune cells (neutrophils and T cells), and not esopha-
geal fibroblasts or endothelial cells [14]. This finding adds to 
earlier observations, describing that neutrophils contributed 
to carcinogenesis by secretion of interleukins [104]. A first 
pilot study also demonstrated feasibility of CXCR4-directed 
imaging for detection of glioblastoma. However, part of the 
PET signal may not arise from specific binding of the tracer 
to CXCR4 but might only be a perfusion effect due to a dam-
aged blood–brain barrier [105].
CXCR4 imaging in cardiovascular disease
Because of its prominent role in inflammation in general, 
and in immune cell regulation in particular, various studies 
have investigated the potential of CXCR4-directed imag-
ing for the detection of hidden infectious foci, or its use 
for visualizing the extent of conditions accompanied by 
inflammation, respectively. In one study,  [68Ga]Pentixafor 
PET/CT identified altered cerebral CXCR4 expression in a 
patient who recently suffered a stroke, corresponding well 
with ischemia-demarcation as assessed by cerebral MRI 
[106]. Multiple studies, examining CXCR4 expression 
after acute myocardial infarction, showed, that the PET sig-
nal correlated with the extent of infarcted myocardium, as 
measured by cardiac MRI [107–110]. In addition, CXCR4 
expression might reveal the myocardial healing potential, as 
assessed by follow-up imaging months after acute myocar-
dial infarction [110]. CXCR4-directed PET imaging has also 
been successfully used to identify atherosclerotic lesions 
[111–113]. Most likely, the elevated CXCR4 expression in 
myocardial infarction and atherosclerotic plaques, as meas-
ured by  [68Ga]Pentixafor PET, originates from infiltrating 
leukocytes to the infarct area and the atherosclerotic lesion, 
respectively [114, 115]. In a recently published study, Li 
et al. were able to show anti-inflammatory effects in athero-
sclerotic lesions of patients that underwent CXCR4-directed 
ERT [116].
CXCR4 imaging in infectious diseases
Imaging CXCR4 expression on infiltrating leukocytes 
might as well be used to track leukocytes that are involved 
in infectious diseases. In a promising first pilot study,  [68Ga]
Pentixafor PET/CT was able to identify chronic bone infec-
tions, with better diagnostic accuracies than anti-granulocyte 
imaging with 99mTc-besilesomab, or 99mTc-labeled white 
blood cells, respectively [117]. Results of another study indi-
cate, that CXCR4-directed PET/MRI with  [68Ga]Pentixafor 
is able to detect infectious foci by imaging leukocyte infil-
tration in patients with complicated urinary tract infections 
after kidney transplantation [118].
Theranostics
As mentioned before, most tumors have a worsening prog-
nosis with increasing CXCR4 expression [119], although 
many of the underlying mechanisms and their implications 
for disease progression are still unknown. For instance, high 
CXCR4 expression on AML blasts correlates with a poor 
prognosis [99, 120], and the protective bone marrow envi-
ronment is considered a major reason for treatment resist-
ance and relapse [121], suggesting potential benefits from 
CXCR4-directed therapies.
Imaging of CXCR4 expression in oncology has mostly 
not been of diagnostic nature until now. Instead, it was 
guided predominantly by theranostic thinking, in pursuit of 
potential therapeutic remedies for patients with otherwise 
limited or non-existent treatment alternatives.
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CXCR4‑targeted radionuclide therapy
Pentixather, the therapeutic twin of Pentixafor, is a promis-
ing CXCR4 ligand that can be labeled with radionuclides 
for ERT [84]. First studies examined the use of Pen-
tixather, labeled with beta-emitters 177Lu or 90Y, for ERT 
of advanced stage MM patients. Although initial response 
rates were high and adverse effects were limited, overall 
survival in this very high-risk cohort was not extended 
[105, 122]. Other pilot investigations showed encouraging 
results using ERT with  [177Lu]/[90Y]Pentixather in diffuse 
large B cell lymphoma (DLBCL; see also Fig. 1) [123] 
and in AML patients, respectively [89]. As of now, there 
is only one prospective trial for CXCR4-directed ERT in 
preparation (COLPRIT trial, Eudra-CT 2015-001817-28), 
that will primarily investigate the tolerable dose and side 
effects of such ERT in patients with MM or lymphoma.
In all cases until now, ERT was performed in addi-
tion to high-dose chemotherapy regimens, followed by 
subsequent hematopoietic stem cell transplantation. It is 
noteworthy that in hematologic diseases with the intent 
to perform allogeneic hematopoietic transplantation, the 
myeloablation by ERT is considered a desired effect to 
allow engraftment of the cellular therapeutic. Opposite to 
that, allogeneic hematopoietic cell transplantation is not an 
established and suitable approach in other malignancies, 
and myeloablation induced by binding of the radionuclide 
to hematopoietic progenitor cells in the bone marrow is 
certainly of major concern. ERT without stem cell rescue 
might be technically feasible for tumors with pronounced 
receptor overexpression as witnessed in adrenocortical 
cancer or small cell lung cancer but requires further devel-
opment and prospective investigations.
Outlook
CXCR4-directed ERT, and particularly—imaging— is 
rapidly gaining popularity at a few academic centers. The 
(pre-)clinically observed dynamics in CXCR4 expression 
(e.g., chemotherapy-induced) present new opportunities 
to potentially modulate CXCR4 expression and function. 
By prior receptor upregulation, imaging might benefit 
from higher sensitivities, and anti-cancer therapies might 
find more targets on the cell surface for a stronger effect. 
Similarly, downregulation of CXCR4 might have synergistic 
effects with conventional therapies. Furthermore, labeling a 
Fig. 1  Example of CXCR4-directed endoradiotherapy with  [90Y]Pen-
tixather (in combination with CD20-directed radioimmunotherapy 
with  [90Y]Zevalin®) as part of the conditioning regimen prior to allo-
geneic stem cell transplantation in relapsed/refractory diffuse large B 
cell lymphoma (DLBCL). Display of maximum intensity projections 
(outer columns) and transaxial slices (inner columns; CT, upper row, 
PET, middle row; PET/CT, lower row) of pre-therapeutic CXCR4-
directed and post-therapeutic  [18F]FDG PET/CT. Post-therapeutic 
imaging was performed 8 weeks after administration of 3.7 GBq of 
 [90Y]Pentixather, 1.2  GBq of  [90Y]Zevalin® as well as conditioning 
chemotherapy with subsequent repeat stem cell transplantation (SCT) 
and demonstrated partial response with residual yet vital pulmonary 
lesions and resolution of all hepatic and nodal DLBCL manifesta-
tions. DLBCL had been relapsed from prior first allogeneic SCT and 
been refractory to all chemotherapeutic regimens
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CXCR4 ligand with an alpha-emitter for ERT might present 
a breakthrough in hematologic malignancies, as the higher 
energy transfer would lead to more effective destruction of 
cancer and cancer-supporting cells.
Summary
CXCR4 and its natural ligand, the chemokine CXCL12, 
play important physiologic roles in embryonic development, 
hematopoiesis and immunity. But the CXCR4-CXCL12 axis 
is also deeply associated with disease and is particularly 
involved in tumor growth and metastasis. A multitude of 
different malignancies overexpress CXCR4 on their respec-
tive cell surface, which predominantly is associated with a 
worse prognosis. Different therapeutics targeting CXCR4 
or its ligand CXCL12 have been developed. For instance, 
Plerixafor, the first FDA-approved CXCR4 inhibitor, mobi-
lizes stem-/progenitor cells from the bone marrow into the 
circulation. Subsequently, various CXCR4-directed imag-
ing tracers were developed, with the positron-emitting PET 
tracer  [68Ga]Pentixafor being the most frequently used today. 
CXCR4 imaging with  [68Ga]Pentixafor has successfully 
been performed in several different malignancies, as well as 
in cardiovascular disease and infections. Its therapeutic twin, 
Pentixather, labeled with the beta-emitters 177Lu or 90Y, has 
already been used for ERT in various hematologic malignan-
cies. Research in the field of CXCR4-directed imaging and 
radionuclide therapy is highly active, and new developments 
over the full spectrum of translational medicine are antici-
pated in the coming years.
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